Solid Net Tangible Assets from 2010 to 2026
| SLDB Stock | USD 6.60 0.05 0.76% |
Net Tangible Assets | First Reported 2015-12-31 | Previous Quarter 183.8 M | Current Value 163.7 M | Quarterly Volatility 100 M |
Check Solid Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Solid Biosciences' main balance sheet or income statement drivers, such as Interest Income of 11.4 M, Depreciation And Amortization of 2.1 M or Interest Expense of 371.4 K, as well as many indicators such as Price To Sales Ratio of 10.66, Dividend Yield of 0.0 or PTB Ratio of 1.12. Solid financial statements analysis is a perfect complement when working with Solid Biosciences Valuation or Volatility modules.
Solid | Net Tangible Assets | Build AI portfolio with Solid Stock |
Analyzing Solid Biosciences's Net Tangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Tangible Assets has evolved provides context for assessing Solid Biosciences's current valuation and future prospects.
Latest Solid Biosciences' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Solid Biosciences LLC over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Solid Biosciences' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Solid Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Solid Net Tangible Assets Regression Statistics
| Arithmetic Mean | 66,519,623 | |
| Geometric Mean | 112,754,828 | |
| Coefficient Of Variation | 207.43 | |
| Mean Deviation | 127,159,057 | |
| Median | 80,048,000 | |
| Standard Deviation | 137,979,562 | |
| Sample Variance | 19038.4T | |
| Range | 339.9M | |
| R-Value | 0.93 | |
| Mean Square Error | 2809.5T | |
| R-Squared | 0.86 | |
| Slope | 25,363,612 | |
| Total Sum of Squares | 304613.8T |
Solid Net Tangible Assets History
About Solid Biosciences Financial Statements
Solid Biosciences stakeholders use historical fundamental indicators, such as Solid Biosciences' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Solid Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Solid Biosciences' assets and liabilities are reflected in the revenues and expenses on Solid Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Solid Biosciences LLC. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 243.4 M | 255.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out the analysis of Solid Biosciences Correlation against competitors. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Solid Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Solid Biosciences LLC requires distinguishing between market price and book value, where the latter reflects Solid's accounting equity. The concept of intrinsic value—what Solid Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Solid Biosciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Solid Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.